

J. Peter KLEIN et al.
Appl. No. 09/544,984
September 10, 2004


Atty. Docket No.: 4377-38

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Claims 1-9 (Canceled)

10. (Original) A compound having the formula



or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) A compound having the formula



or a pharmaceutically acceptable salt thereof.

Claims 12-17 (Canceled)


18. (Currently Amended) A pharmaceutical composition comprising the compound as defined in any of claims ~~8-15~~ 10, 11 or 47-49, ~~in which the compound is an~~ in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.

Claims 19-46 (Canceled)

47. (Previously Presented) A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula (I):

J. Peter KLEIN et al.
 Appl. No. 09/544,984
 September 10, 2004

Atty. Docket No.: 4377-38



wherein:

X is $N(R_3)$, Y is NH or $N(CH_3)$ and Z is $C(R_4)$, where R_3 is H, CH_3 or $CH_2OCH_2CH_3$, and R_4 is selected from the group consisting of $C_{(1-20)}$ alkylamino, $C_{(1-20)}$ alkylaminoalkyl, $C_{(1-20)}$ aminoalkyl, $C_{(1-20)}$ aminoalkoxyalkenyl, $C_{(1-20)}$ aminoalkoxyalkenyl, $C_{(1-20)}$ diaminoalkyl, $C_{(1-20)}$ triaminoalkyl, $C_{(1-20)}$ tetraaminoalkyl, $C_{(5-15)}$ aminotrialkoxyamino, $C_{(1-20)}$ alkylamido, $C_{(1-20)}$ alkylamidoalkyl, $C_{(1-20)}$ amidoalkyl, $C_{(1-20)}$ acetamidoalkyl;

R_1 is $-(CH_2)_n-CHOH-CH_3$ which may be substituted with a member of the group consisting of acylamino and $-NR^aR^b$, wherein each of R^a and R^b may be the same or different and each is selected from the group consisting of hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclic group; and n is 3-7; and

R_2 is hydrogen or methyl.

48. (Previously Presented) The therapeutic compound of claim 47 wherein R_1 is $-(CH_2)_n-CHOH-CH_3$, X is $N(CH_3)$, Y is NH, and R_4 is $C_{(1-20)}$ alkylaminoalkyl.

49. (Previously Presented) The therapeutic compound of claim 47 wherein R_1 is $-(CH_2)_n-CHOH-CH_3$ which the hydroxy group is substituted with $-NR^aR^b$, wherein each of R^a and R^b may be the same or different and each is selected from the group consisting of hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclic group, X is $N(CH_3)$, Y is NH, and R_4 is hydrogen.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.